Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Revlimid results look promising for multiple myeloma patients

The Multiple Myeloma Research Foundation (MMRF) applauded today's Celgene announcement regarding Revlimid, a new class of novel immunomodulatory drugs currently being evaluated to treat a broad range of hematology and oncology conditions, including multiple myeloma.

8 Mar 2005

Two chemicals boost immune cells' ability to fight HIV without gene therapy

A UCLA AIDS Institute study has discovered that two chemical compounds may help the immune systems of HIV-infected persons fight the disease without invasive gene therapy.

7 Mar 2005

Phase 1 clinical trials have greater response rates than had been previously believed

A new study by the Department of Clinical Bioethics at the National Institutes of Health, has found that twice as many cancer patients testing medications in early, phase 1 clinical trials have positive response rates than had been previously believed.

3 Mar 2005

Experts on chronic lymphocytic leukemia (CLL) review current scientific knowledge

When the most common adult leukemia in the United States was last reviewed by the New England Journal of Medicine (NEJM) in 1995, it was seen through the eyes of theories that dated back to the 1960s.

24 Feb 2005

Protein called CK2 plays a deadly role in colorectal carcinoma

A protein called CK2 plays a deadly role in colorectal carcinoma by blocking the ability of these tumors to activate a natural self-destruct mechanism that would clear this cancer from the body. This finding, by researchers at St. Jude Children's Research Hospital, is currently published in the online edition of Oncogene.

24 Feb 2005

Feverfew or Bachelor's Button, kills human leukemia stem cells like no other single therapy

A daisy-like plant known as Feverfew or Bachelor's Button, a traditional remedy for reducing fevers and a treatment for nervousness, hysteria and low spirits, is the source of an agent that kills human leukemia stem cells like no other single therapy

23 Feb 2005

New compound, AMN107, 20 times more potent than Gleevec for chronic myelogenous leukemia treatment

A laboratory study led by researchers at Dana-Farber Cancer Institute has shown that a potent and highly selective therapy for chronic myelogenous leukemia (CML) may ultimately be more effective than Gleevec®, the current standard of care.

21 Feb 2005

Antigens produced by the Epstein Barr virus may provide an ideal target for cancer therapy

A typically innocuous virus found in 90 percent of people worldwide is the key to a new treatment for a cancer particularly common in North Africa and Southeast Asia.

16 Feb 2005

Green tea extract has potential as an anti-cancer agent

A new study on bladder cancer cells lines shows that green tea extract has potential as an anti-cancer agent, proving for the first time that it is able to target cancer cells while leaving healthy cells alone.

15 Feb 2005

Clot-dissolving drugs such as tPA may help detect potentially deadly leg clots

A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.

14 Feb 2005

Origins of skin cancer melanoma

Researchers at Children's Hospital Boston and the Dana-Farber Cancer Institute have found an important clue about the origins of the deadly skin cancer melanoma.

7 Feb 2005

Cord blood transplantation now a viable option for adult leukemia patients

Stem cell transplantation using umbilical cord blood is a standard treatment option for blood disorders in children, but not for adults, due to the difficulty of obtaining a sufficiently large dose of cells.

20 Jan 2005

Researchers to test new leukemia drug

Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.

12 Jan 2005

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.

10 Jan 2005

Potential cure for lymphoma in HIV patients

Stem cell transplants have become the standard of care for patients with relapsed lymphoma, but not for patients who suffer from both this disease and HIV.

7 Jan 2005

First assessment tool to evaluate Quebec Platelet Disorder (QPD)

Researchers at McMaster University have developed the first assessment tool of its kind for evaluating risks faced by Canadians suffering from a rare and often fatal bleeding disorder.

22 Dec 2004

Dramatic changes in the way the FDA address patient safety are needed

Food and Drug Administration policies prevent pharmaceutical manufacturers from informing patients about potentially fatal toxicities that occur with some cancer drugs -- policies that should be revised immediately, according to Northwestern University researchers.

20 Dec 2004

Link found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw

Doctors at Long Island Jewish (LIJ) Medical Center recently discovered a link between a common chemotherapy drug and a serious bone disease called osteonecrosis of the jaw (ONJ).

13 Dec 2004

Zarnestra, a farnesyl transferase inhibitor, can help treat high-risk myelodysplastic syndrome patients

An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

7 Dec 2004

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.